edoc

Corona immunitas: study protocol of a nationwide program of SARS-CoV-2 seroprevalence and seroepidemiologic studies in Switzerland

West, E. A. and Anker, D. and Amati, R. and Richard, A. and Wisniak, A. and Butty, A. and Albanese, E. and Bochud, M. and Chiolero, A. and Crivelli, L. and Cullati, S. and d'Acremont, V. and Epure, A. M. and Fehr, J. and Flahault, A. and Fornerod, L. and Frank, I. and Frei, A. and Michel, G. and Gonseth, S. and Guessous, I. and Imboden, M. and Kahlert, C. R. and Kaufmann, L. and Kohler, P. and Mösli, N. and Paris, D. and Probst-Hensch, N. and Rodondi, N. and Stringhini, S. and Vermes, T. and Vollrath, F. and Puhan, M. A. and Corona Immunitas Research Group, . (2020) Corona immunitas: study protocol of a nationwide program of SARS-CoV-2 seroprevalence and seroepidemiologic studies in Switzerland. International journal of public health, 65. pp. 1529-1548.

[img] PDF - Published Version
Available under License CC BY (Attribution).

1329Kb

Official URL: https://edoc.unibas.ch/91245/

Downloads: Statistics Overview

Abstract

OBJECTIVES; : Seroprevalence studies to assess the spread of SARS-CoV-2 infection in the general population and subgroups are key for evaluating mitigation and vaccination policies and for understanding the spread of the disease both on the national level and for comparison with the international community.; METHODS; : Corona Immunitas is a research program of coordinated, population-based, seroprevalence studies implemented by Swiss School of Public Health (SSPH+). Over 28,340 participants, randomly selected and age-stratified, with some regional specificities will be included. Additional studies in vulnerable and highly exposed subpopulations are also planned. The studies will assess population immunological status during the pandemic.; RESULTS; : Phase one (first wave of pandemic) estimates from Geneva showed a steady increase in seroprevalence up to 10.8% (95% CI 8.2-13.9, n = 775) by May 9, 2020. Since June, Zurich, Lausanne, Basel City/Land, Ticino, and Fribourg recruited a total of 5973 participants for phase two thus far.; CONCLUSIONS; : Corona Immunitas will generate reliable, comparable, and high-quality serological and epidemiological data with extensive coverage of Switzerland and of several subpopulations, informing health policies and decision making in both economic and societal sectors. ISRCTN Registry: https://www.isrctn.com/ISRCTN18181860 .
Faculties and Departments:09 Associated Institutions > Swiss Tropical and Public Health Institute (Swiss TPH)
09 Associated Institutions > Swiss Tropical and Public Health Institute (Swiss TPH) > Department of Epidemiology and Public Health (EPH) > Chronic Disease Epidemiology > Exposome Science (Probst-Hensch)
03 Faculty of Medicine > Departement Public Health > Sozial- und Präventivmedizin > Exposome Science (Probst-Hensch)
03 Faculty of Medicine > Departement Public Health > Sozial- und Präventivmedizin > Medicines Development (Paris)
09 Associated Institutions > Swiss Tropical and Public Health Institute (Swiss TPH) > Department of Medicine (MED) > Medicines Development (Paris)
UniBasel Contributors:D'Acremont, Valérie and Imboden, Medea and Mösli, Nicolai and Paris, Daniel Henry and Probst-Hensch, Nicole and Vermes, Thomas
Item Type:Article, refereed
Article Subtype:Research Article
ISSN:1661-8556
Note:Publication type according to Uni Basel Research Database: Journal article
Language:English
Related URLs:
Identification Number:
edoc DOI:
Last Modified:29 Dec 2022 14:33
Deposited On:29 Dec 2022 14:33

Repository Staff Only: item control page